Bariatric Surgery

The disease of obesity often brings cardiometabolic consequences, including hypertension, which remains the most potent and predictive risk factor for cardiovascular disease.

In a single-center cohort of patients with heart failure and obesity, weight-loss surgery led to improved clinical outcomes including reduced BMI and HbA1c and less reliance on diuretics, researchers reported.

In patients with obesity and obstructive sleep apnea, those who had weight-loss surgery had approximately 40% reduced risk for major adverse CV events and death compared with those who did not, according to the results of the MOSAIC study.

Survodutide has an “acceptable safety profile” in patients with metabolic dysfunction-associated steatohepatitis with compensated and decompensated cirrhosis, with no dose reduction needed based on pharmacokinetics, according to data.

LPCN 1148, an oral androgen receptor agonist, improved sarcopenia in men with advanced cirrhosis as early as week 12 — with sustained improvement through 52 weeks — and reduced recurrence of encephalopathy, according to late-breaking data.

NEW YORK — In this Healio Video Perspective from the American Psychiatric Association annual meeting, Candace Hatten-Powell, MD, talks about opioid-sparing medications that may be used following bariatric surgery.

At 15 years of follow-up, metabolic surgery “was not only safe” but also significantly reduced major adverse liver outcomes and decompensation in patients with metabolic dysfunction-associated steatohepatitis and compensated cirrhosis.

PHILADELPHIA — Older adults with end-stage kidney disease undergoing bariatric surgery may be more likely to achieve kidney transplant, according to data presented at the American Transplant Congress.

CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting.